Alumis (ALMS) Equity Ratio (2023 - 2025)

Alumis (ALMS) reported Equity Ratio of 0.73 for Q4 2025, down 4.11% year-over-year from 0.76 in Q4 2024, and down 7.23% quarter-over-quarter from 0.79 in Q3 2025.

Alumis (ALMS) Equity Ratio (2023 - 2025) Analysis & Trends

Alumis (ALMS) has 3 years of Equity Ratio data on file, last reported at 0.73 in Q4 2025.

  • Equity Ratio for Q4 2025 came in at 0.73, down 4.11% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.73 (down 4.11% YoY), and the FY2025 annual result was 0.73, down 4.11% from the prior year.
  • Equity Ratio fell to 0.73 in Q4 2025 per ALMS's latest filing, from 0.79 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.84 in Q3 2024 and troughed at 3.79 in Q4 2023.
  • A 3-year average of 0.11 and a median of 0.75 in 2024 frame the typical range for Equity Ratio.
  • On a YoY basis, Equity Ratio climbed as much as 148.01% in 2025 and fell as far as 6.63% in 2025.
  • A 3-year view of Equity Ratio shows it stood at 3.79 in 2023, then jumped by 120.15% to 0.76 in 2024, then declined by 4.11% to 0.73 in 2025.
  • Business Quant data shows ALMS's Equity Ratio at 0.73 in Q4 2025, 0.79 in Q3 2025, and 0.79 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 191.07
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 0.98
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 0.04
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.58
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 0.42
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 0.73
9 Abivax 91.96 Bn 91.96 Bn - 0.79
10 Alumis 1.99 Bn 1.90 Bn - 0.73

Historic Data

Download Data
DateValue
Dec 31, 2025 0.73
Sep 30, 2025 0.79
Jun 30, 2025 0.79
Mar 31, 2025 0.64
Dec 31, 2024 0.76
Sep 30, 2024 0.84
Jun 30, 2024 -1.65
Dec 31, 2023 -3.79